• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sen. Kay Hagan introduces TREAT Act to accelerate patient access to certain medicines

Sen. Kay Hagan introduces TREAT Act to accelerate patient access to certain medicines

February 17, 2012
CenterWatch Staff

Senator Kay R. Hagan (D-N.C.) has introduced the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act, to get targeted treatments to patients with serious or life-threatening diseases in a quick and safe manner.

The bill will be referred to the Senate Health, Education, Labor and Pensions (HELP) Committee, which oversees healthcare issues, and of which Hagan is a member.

If passed, the TREAT Act would accelerate the review and approval process for medicines that: treat an unmet medical need; significantly advance the standard of care; or are highly-targeted therapies for serious or life-threatening diseases or conditions.
 
"The TREAT Act is a common-sense bill that will get innovative treatments to patients more quickly, while maintaining FDA's high standards for safety and effectiveness," said Hagan. "Accelerated approval processes helped HIV and cancer treatments advance by leaps and bounds in the 1990s. For patients suffering today from rare diseases for which there are no current treatments, medical advances can't come fast enough. This legislation creates a consistent process and a clear and effective pathway at FDA that will encourage the development of innovative treatments for patients otherwise dependent on the uncertainty of medical breakthroughs.”

The bill would enhance the FDA's access to external scientific and medical expertise. It allows the FDA Commissioner to better utilize waivers when potential conflicts of interest are outweighed by the need to have input from leading medical and scientific experts. It also recommends that patient and disease research organizations have more representation on FDA advisory committees, which is critical in areas in which research is on the cutting edge.

The TREAT Act also would ensure the FDA provides drug sponsors with explanations when their drugs are turned down so that they might address concerns, improve the treatment and get approved medications to patients more quickly. Furthermore, the bill updates the FDA Mission Statement to reflect the FDA's role in advancing medical innovation while promoting and strengthening the agency's safety and effectiveness standards.

The bill establishes new positions to promote innovation, integration and oversight, as well as a Management Review Board to help the FDA keep pace with advancing medical innovation and ensure that safety precautions are adhered to.

The TREAT Act already has gained support from the National Organization for Rare Disorders (NORD) and the Friends of Cancer Research.

"NORD appreciates that Senator Hagan and her staff have listened to the concerns of rare disease patients in drafting this proposed legislation," said Peter L. Saltonstall, president and CEO of NORD. "We look forward to working with Senator Hagan in support of this effort to accelerate the process for bringing safe, effective therapies to patients who desperately need them."

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing